Royalty Pharma plc (RPRX)
| Market Cap | 38.76B +140.4% |
| Revenue (ttm) | 2.62B +11.4% |
| Net Income | 672.45M -12.0% |
| EPS | 1.53 -12.5% |
| Shares Out | 573.61M |
| PE Ratio | 44.12 |
| Forward PE | 11.98 |
| Dividend | $0.94 (1.39%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 4,900,587 |
| Open | 68.00 |
| Previous Close | 67.56 |
| Day's Range | 67.51 - 69.77 |
| 52-Week Range | 36.03 - 69.77 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 65.38 (-3.24%) |
| Earnings Date | Nov 4, 2026 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune ... [Read more]
Financial Performance
In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RPRX stock is "Buy." The 12-month stock price target is $65.38, which is a decrease of -3.24% from the latest price.
News
Royalty Pharma price target raised to $75 from $67 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $75 from $67 and keeps an Overweight rating on the shares. The company raised 2026 guidance again following…
Royalty Pharma Slides: Corporate presentation
Royalty Pharma has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Royalty Pharma price target raised to $78 from $70 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Royalty Pharma (RPRX) to $78 from $70 and keeps a Buy rating on the shares. The firm views the company’s…
Royalty Pharma price target raised to $74 from $62 at JPMorgan
JPMorgan raised the firm’s price target on Royalty Pharma (RPRX) to $74 from $62 and keeps an Overweight rating on the shares. The company posted good momentum across the portfolio…
Royalty Pharma Earnings Call Transcript: Q3 2026
Q3 portfolio receipts rose 9%, and YTD royalty receipts grew 12%; 2026 guidance was raised for a third consecutive quarter. Returns remained attractive, while new royalties and a broad development pipeline support long-term growth.
Royalty Pharma Earnings release: Q3 2026
Royalty Pharma released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Royalty Pharma Slides: Q3 2026
Royalty Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Royalty Pharma Quarterly report: Q3 2026
Royalty Pharma has published its Q3 2026 quarterly earnings report on November 4, 2026.
Royalty Pharma reports third quarter 2026 results
Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to ...
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Royalty Pharma declares fourth quarter 2026 dividend
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordi...
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will h...
Royalty Pharma price target raised to $67 from $65 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $67 from $65 and keeps an Overweight rating on the shares. The firm adjusted its models for its…
Royalty Pharma Transcript: Bank of America Global Healthcare Conference
The conference highlighted scenario-based modeling for policy risks, strategic AI investments, and a focus on scalable deal structures like synthetic royalties. Geographic expansion in China and dynamic capital allocation support strong portfolio growth and diversification.
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy ...
Royalty Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Achieved capital deployment targets ahead of schedule, driven by robust deal flow and new opportunities in Big Pharma and China. R&D co-funding and synthetic royalties are expanding, supported by proprietary data and AI capabilities. Innovative deal structures and a strategic push into China are expected to drive long-term growth.
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligo...
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma
Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma’s economics related to rusfertide, a potential...
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics rela...
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will re...
Royalty Pharma Slides: Corporate presentation
Royalty Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Royalty Pharma price target raised to $66 from $59 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $59 and keeps a Buy rating on the shares.
Royalty Pharma price target raised to $65 from $64 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $65 from $64 and keeps an Overweight rating on the shares, noting that the company raised 2026 guidance…
Royalty Pharma price target raised to $70 from $66 at Citi
Citi raised the firm’s price target on Royalty Pharma (RPRX) to $70 from $66 and keeps a Buy rating on the shares. The firm views the company’s Q2 report as…